First patent granted to Norwood Immunology
Tuesday, 17 February, 2004
Norwood Abbey (ASX:NAL) subsidiary Norwood Immunology has been granted its first patent, covering the use of GnRH analogues to increase the T cell population for the treatment of a variety of diseases.
The patent, granted in South Africa, is the first of more than 100 patent applications filed in major jurisdictions around the world covering various aspects of the immunology project.
Director of marketing Bernie Romanin said that the granted patent provided recognition of the breadth of the application of the GnRH technology.
Norwood Immunology is in the process of listing on the London Stock Exchange's AIM market. Romanin said the listing process was progressing according to plan and the company expected it to list mid-year.
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
